IGES Pharma offers a unique approach when supporting biotech and pharma clients. Our flexible approach, technically excellent teams, the use of first-class data enable rapid decision making throughout the drug development and commercialization process. As a result, our clients are able to rapidly and sustainably access the leading European markets and reach European patients. Clinical research is combined with market analysis and real world data - to the benefit of our customers.
A partner with the right therapeutic expertise can help you optimize the strategy and execution of your programs. This applies equally to clinical development, market access and reimbursement.
Our experts understand the intricacies of your therapeutic area and indication, and they know the regulatory requirements and their impact on market access and reimbursement. We ensure that your project is led by a hand-picked team with specific experience in reimbursement and HTA agency assessments that are critical to your indication.
At IGES Pharma, we have extensive expertise and are able to leverage the vast data available from a wide variety of sources - including real world data. This makes us a clinical development and commercialization partner like no other. You want the right therapies to reach the right patients quickly. We want to help you achieve that goal on a predictable path.
If you would like to receive information about IGES Pharma and our work, please do not hesitate to contact me.
Dr Tilo Mandry
Director Business Development International
Tilo Mandry is responsible for international business development at IGES Group. He supports international companies in accessing European markets. Tilo Mandry has many years of experience in the life science and high-tech industry. His main focus is on digital health, innovative drugs for rare diseases and innovative medical technologies. He is a fully qualified lawyer and holds a doctorate in the field of pharmaceutical law (from the Research Center for Pharmaceutical Law at the University of Marburg), as well as a Master of Laws from Vanderbilt University in the USA with a research focus on phamarcogenomics.
Phone: +49 30 230 80 90